Food Allergy Science Initiative

What Food Allergy Science Initiative does

Food Allergy Science Initiative (FASI) is an independent 501(c)(3) nonprofit research organization founded in 2016 at the Broad Institute of MIT and Harvard and spun out as a standalone entity in 2021. It operates as a research accelerator coordinating more than 100 scientists across 20+ world-class laboratories at institutions including Harvard, Yale, Rockefeller University, the Broad Institute, and the Icahn School of Medicine at Mount Sinai. The organization channels philanthropic donations and federal grants — notably multi-year awards from the NIH's National Institute of Allergy and Infectious Diseases — into interdisciplinary food allergy research spanning immunology, neuroscience, gastroenterology, microbiology, and computational biology, with the explicit mission of advancing diagnosis, treatment, and ultimately a cure for food allergies.

FASI's core technical assets include proprietary Gut Cell and Enteric Nervous System Atlases, high-throughput single-cell RNA sequencing platforms developed by MIT researchers, and CRISPR-based genetic screening systems used to evaluate candidate genes in peripheral neurons. These capabilities have produced 157 published research projects, 11,344+ citations, and 6 patents for diagnostics and treatments. Its programmatic offerings center on the FASI Research Network, the monthly 'Food For Thought' seminar series, the annual FASI Symposium, and the upcoming FASI 10 Anniversary Research Summit in October 2026.

FASI is funded entirely through donations (100% directed to research) and government grants, with no commercial product revenue. Its 'customers' are the patient community of 32 million Americans and 520 million people worldwide living with food allergies, the scientific research community it convenes, and the philanthropic donors and federal agencies that fund its work. Strategic collaborators include ARPA-H (as an Investor Catalyst Hub spoke member), Vie Ventures (as a strategic collaborator for immune-mediated disease therapeutics), and a network of leading academic medical centers.

Name

Food Allergy Science Initiative

Legal name

Food Allergy Science Initiative, Inc.

Website

https://foodallergyscience.org

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

Food Allergy Science Initiative is a 501(c)(3) nonprofit research accelerator coordinating 100+ scientists across 20+ laboratories to drive breakthrough discoveries in food allergy diagnosis, treatment, and prevention, funded entirely by philanthropy and federal grants.

Ownership category

akta.pro rank

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Philanthropic Donations: 100% of philanthropic donations directly support groundbreaking research. Donors can give online, by mail, wire transfer, stock transfer, or through Donor Advised Funds. Federal Tax ID: 85-1293789.
2. Government Research Grants: Landmark research grants from federal agencies including the National Institute of Allergy and Infectious Diseases (NIAID) to support neuroimmune research. Multi-year NIH collaborative grants.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels8 records

Core offering

FASI is a nonprofit research accelerator that funds, coordinates, and convenes a collaborative scientific network of 100+ investigators across 20+ laboratories (Harvard, Yale, Rockefeller, Broad Institute, Icahn School of Medicine) to drive high-impact food allergy discoveries. Its programmatic offerings include the Food For Thought monthly seminar/webinar series, an Annual Symposium, the FASI 10 Anniversary Research Summit, and the underlying funded research projects themselves, with outputs measured in peer-reviewed publications, patents, atlases (Gut Cell Atlas, Enteric Nervous System Atlas), and translational pathways toward therapeutics.

Product overview

The Food Allergy Science Initiative (FASI) is a nonprofit research accelerator, not a traditional product company. It operates a collaborative research network that brings together over 100 scientists across 20+ laboratories at premier institutions including Harvard, Yale, and the Broad Institute. FASI's core offerings include the FASI Research Network itself, the Food For Thought Seminar Series (monthly webinars), the Annual Symposium, and the FASI 10 Anniversary Research Summit. These programs support high-impact discoveries in food allergy science through interdisciplinary collaboration spanning immunology, neuroscience, gastroenterology, microbiology, and computational biology. FASI does not offer commercial products; its outputs are scientific discoveries, publications, and therapeutic innovations aimed at understanding, treating, and curing food allergies.

Differentiator

Problem solved

Functional benefit

Products and services

• FASI Research Network A collaborative research network coordinating over 100 scientists across 20+ world-class laboratories at institutions including Harvard, Yale, Rockefeller University, the Broad Institute, and Icahn School of Medicine, focused on advancing food allergy science through interdisciplinary collaboration.
• FASI Seminar Series (Food For Thought) A monthly webinar series showcasing foundational and innovative research being done to find a cure for food allergies, featuring presentations from FASI scientists and external experts on topics including allergy treatments, immunotherapy approaches, and neuroimmune research.
• FASI Annual Symposium An annual scientific symposium bringing together experts from around the globe to accelerate breakthrough scientific discoveries that transform the lives of people living with food allergies, showcasing cutting-edge allergy research.
• FASI 10 Anniversary Research Summit A landmark research summit celebrating a decade of food allergy science, scheduled for October 6-7, 2026 at the Broad Institute of MIT & Harvard, bringing together top minds in food allergy research and treatment, industry partners, and community members.

Quantifiable outcome

• 520 million people worldwide affected by food allergies with no known cure
• +3 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Nine partnerships are on record, tiered core and minor.

• Vie VenturescoreStrategic or Co-development Partner · 23 June 2026FASI joined Vie Ventures as a Strategic Collaborator, bringing its network of over 100 scientists across 20+ laboratories to contribute scientific and clinical expertise toward Vie Ventures' investment and portfolio development activities in food allergy and immune-mediated diseases. The collaboration aims to accelerate therapeutic innovation, joining a network that includes Crohn's & Colitis Foundation and National Multiple Sclerosis Society.
• ARPA-H Investor Catalyst HubcoreStrategic or Co-development Partner · 11 June 2025FASI was selected as a spoke member of the ARPA-H Investor Catalyst Hub, a regional hub of ARPANET-H, a nationwide health innovation network. This aligns with FASI's mission to drive bold, science-based solutions for food allergies and provides access to potential funding, flexible contracting, and networking opportunities.
• Crohn's & Colitis FoundationminorStrategic or Co-development PartnerPart of Vie Ventures' network of leading disease philanthropies focused on advancing therapeutic innovation across immune-mediated diseases.
• National Multiple Sclerosis SocietyminorStrategic or Co-development PartnerPart of Vie Ventures' network of leading disease philanthropies focused on advancing therapeutic innovation across immune-mediated diseases.
• Broad Institute of MIT and HarvardcoreStrategic or Co-development PartnerFASI was founded at the Broad Institute in 2016 and maintains its headquarters there. The Broad Institute provides institutional support and serves as the anchor institution for FASI's research network.
• Yale School of MedicinecoreStrategic or Co-development PartnerKey research partner home to Scientific Founder Ruslan Medzhitov and multiple principal investigators. Hosts the Medzhitov lab and conducts significant food allergy research.
• Harvard Medical School and Affiliated HospitalscoreStrategic or Co-development PartnerNetwork includes Massachusetts General Hospital, Brigham and Women's Hospital, and Boston Children's Hospital. Home to multiple FASI investigators including Stephen Liberles and Isaac Chiu.
• Rockefeller UniversitycoreStrategic or Co-development PartnerResearch partner home to FASI Principal Investigator Daniel Mucida. Key institution in the collaborative research network.
• Icahn School of Medicine at Mount SinaicoreStrategic or Co-development PartnerResearch partner contributing to FASI's collaborative network of top scientists working on food allergy research.

Scale indicators11 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Food Allergy Research & Education (FARE): The largest US patient advocacy nonprofit focused on food allergy research, education, and advocacy. Direct peer to FASI as the other major nonprofit funder of food allergy science, also distributing grants to academic investigators and raising philanthropic dollars.
• Sean N. Parker Center for Allergy and Asthma Research at Stanford: Philanthropically funded academic research center at Stanford focused on allergy and asthma, including food allergy immunology and novel therapeutics. Direct peer given shared nonprofit-funded academic research model targeting food allergy mechanisms.
• Jaffe Food Allergy Institute at Mount Sinai: Academic research institute within the Icahn School of Medicine at Mount Sinai dedicated to food allergy diagnosis, treatment, and prevention research. Direct peer given overlapping investigator relationships (FASI lists Mount Sinai as a core research partner) and shared food allergy research mandate.

Broad incumbents

• Aimmune Therapeutics (Nestlé Health Science): Developer of Palforzia, the first FDA-approved oral immunotherapy for peanut allergy, now part of Nestlé Health Science. Broad incumbent comparable to FASI because it operates in the same therapeutic end-market (food allergy treatment) but with a commercial pharmaceutical business model.
• DBV Technologies: Public clinical-stage biopharmaceutical company developing epicutaneous immunotherapy (Viaskin patch) for food allergies, including milk and peanut. Broad incumbent comparable to FASI because it pursues food allergy therapeutics through a different delivery modality and commercial vehicle.
• Chan Zuckerberg Initiative (Rare As One Network): Philanthropic organization funding collaborative biomedical research networks, including rare disease initiatives that bring together scientists, clinicians, and patient communities. Broad incumbent comparable to FASI through its nonprofit research accelerator model and patient-driven scientific network structure.
• Howard Hughes Medical Institute (HHMI): Largest US biomedical research philanthropy, supporting ~300 HHMI Investigators across universities. Broad incumbent because multiple FASI PIs (Medzhitov, Liberles, Mucida) are HHMI Investigators, and HHMI provides a comparable model of distributed investigator funding that FASI emulates for food allergy specifically.

Emerging players

• Alladapt Immunotherapeutics: Clinical-stage biopharmaceutical company developing oral immunotherapy (ADP101) for multi-food allergy. Emerging player with partial overlap in food allergy immunotherapy that intersects with FASI's research network, but operates via a traditional biotech funding model.
• Arc Institute: Nonprofit research organization founded in 2021 that operates a collaborative model similar to FASI's, supporting high-impact biomedical research across immunology, genomics, and computational biology. Emerging player because the institutional model (nonprofit research accelerator supporting distributed scientists) is closely comparable.

Others

• Allen Institute: Philanthropically funded nonprofit research organization producing large-scale public atlases (brain, cell, immune) via collaborative science. Comparable to FASI through shared model of generating foundational scientific atlases as community resources and cross-disciplinary investigator coordination.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubevimeo.com/foodallergyscience
• LinkedInlinkedin.com/company/foodallergyscienceinitiative
• Instagraminstagram.com/foodallergyresearch
• Xx.com/foodallergysci
• Facebookfacebook.com/FoodAllergyScience

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Food Allergy Science Initiative